[HVB and HVC infections in nephrology].
Pol
S
S
Unité d'hépatologie, Hôpital Necker, Paris.
D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D000075202:Contraindications; D006084:Graft Rejection / Q000517:prevention & control; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D016898:Interferon-alpha; D007674:Kidney Diseases / Q000453:epidemiology* / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects; D019259:Lamivudine / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D006435:Renal Dialysis / Q000009:adverse effects; D012254:Ribavirin / Q000627:therapeutic use; D014611:Vaccination; D014761:Viral Hepatitis Vaccines; D014766:Viremia / Q000209:etiology / Q000635:transmission
D000998:Antiviral Agents; D016898:Interferon-alpha; D014761:Viral Hepatitis Vaccines; D019259:Lamivudine; D012254:Ribavirin